KOD Projected Dividend Yield
Kodiak Sciences Inc ( NASDAQ : KOD )Kodiak Sciences is a clinical stage biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform™ (ABC Platform™) uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, tarcocimab, is an anti-vascular endothelial growth factor antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, and wet age-related macular degeneration. Co. has utlized its ABC Platform to build a pipeline of product candidates in various stages of development. 20 YEAR PERFORMANCE RESULTS |
KOD Dividend History Detail KOD Dividend News KOD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |